Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case–control study of adalimumab and methotrexate - Takeaways - MDSpire

Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case–control study of adalimumab and methotrexate

  • By

  • Eisa M. Hegazy

  • Eslam Abdelfattah Sadek

  • Shimaa Saber Ahmed

  • March 18, 2026

  • 0 min

Share

  • 1

    Psoriasis affects 2-3% of the global population and can lead to psoriatic arthritis in up to 40% of patients, significantly impairing quality of life.

  • 2

    TWEAK, a cytokine linked to inflammation, plays a role in psoriatic disease, but its effects on treatment outcomes with adalimumab and methotrexate are not well understood.

  • 3

    This study evaluates serum TWEAK levels before and after treatment with adalimumab for psoriasis and methotrexate for psoriatic arthritis.

  • 4

    Clinical assessments included PASI for psoriasis severity and DAPSA for psoriatic arthritis activity, measured at baseline and 24 weeks.

  • 5

    The study design reflects real-world therapeutic standards, with a minimum of 20 participants per group to ensure sufficient statistical power.

Original Source(s)

Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case–control study of adalimumab and methotrexate

  • by Eisa M. Hegazy, Eslam Abdelfattah Sadek, Shimaa Saber Ahmed

  • March 18, 2026

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

He Needs an Expensive Drug. A Copay Card Helped — Until It Didn’t. - KFF Health News

Case report : Early-Onset Juvenile Psoriatic Arthritis Presenting at 15 Months: A Diagnostic Challenge in Infancy